UNSPSC 51434956: Quinethazone/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434956 Quinethazone/reserpine is a Commodity code capturing individual pharmaceutical products and active ingredients procured by state and local health agencies, emergency services, and cooperative purchasing alliances. State and local governments buy under this code primarily through emergency medical services procurement (Advanced Life Support medications for fire departments), state Medicaid and health commission pharmacy programs, and multistate cooperative purchasing agreements that aggregate demand across multiple jurisdictions for generic pharmaceuticals and over-the-counter products. Issuing bodies include municipal purchasing departments (fire rescue services), state health and human services commissions, state procurement offices administering multistate cooperatives, and participating hospital and health system networks within those alliances. Recent solicitations show a mix of direct-to-wholesaler arrangements and manufacturer-direct contracts, with vendors required to maintain FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and detailed product traceability documentation including National Drug Codes and Safety Data Sheets.

Geographic activity concentrates in Florida, Texas, and Minnesota, with multistate reach through cooperative purchasing vehicles. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) for Tampa Fire Rescue with response due April 8, 2026 and estimated value of $40,000; the contract includes a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with response due March 26, 2026, requiring NDC-level product specifications, wholesaler relationships with AmerisourceBergen, Cardinal Health, and Morris & Dickson, and pricing flexibility across flat and net-price formats.